Autoimmune blistering diseases of the skin

Autoimmunity Reviews

Volumn 11, Issue 3, 2012, Pages 226-230

  Sticherling, Michael ^a   Erfurt Berge, Cornelia ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Autoimmune blistering diseases; Autoimmune skin diseases; Bullous autoimmune diseases; Dermatitis herpetiformis; Epidermolysis bullosa aquisita; Pemphigoid; Pemphigus

Indexed keywords

CORTICOSTEROID; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G;

ANTIBODY RESPONSE; AUTOIMMUNE BULLOUS DISEASE; AUTOIMMUNE SKIN DISEASE; BASEMENT MEMBRANE; BULLOUS PEMPHIGOID; BULLOUS SKIN DISEASE; DERMATITIS HERPETIFORMIS; DERMIS; DISEASE CLASSIFICATION; EPIDERMIS; EPIDERMOLYSIS BULLOSA ACQUISITA; HUMAN; IGA PEMPHIGUS; LINEAR IMMUNOGLOBULIN A DISEASE; MUCOUS MEMBRANE PEMPHIGOID; NONHUMAN; PARANEOPLASTIC PEMPHIGUS; PEMPHIGOID GESTATIONIS; PEMPHIGUS FOLIACEUS; PEMPHIGUS VULGARIS; REVIEW;

ADRENAL CORTEX HORMONES; AUTOANTIGENS; AUTOIMMUNE DISEASES; BLISTER; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOGLOBULIN A; SKIN;

EID: 84855926811     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2011.05.017     Document Type: Review

References (39)

1. Patricio P., Ferreira C., Gomes M.M., Filipe P. Autoimmune bullous dermatoses: a review. Ann N Y Acad Sci 2009, 1173:203-210.
2. Murrell D.F., Dick S., Ahmed A.R., Amagai A., Barnadas M.A., Borradori L., et al. Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. J Am Acad Dermatol 2008, 58:1043-1046.
3. Nagel A., Lang A., Engel D., Podstawa E., Hunzelmann N., de Pita O., et al. Clinical activity of pemphigus vulgaris relates to IgE autoantibodies against desmoglein 3. Clin Immunol 2010, 134:320-330.
4. Qian Y., Diaz L.A., Ye J., Clarke S.H. Dissecting the anti-desmoglein autoreactive B cell repertoire in pemphigus vulgaris patients. J Immunol 2007, 178:5982-5990.
5. Grando S.A., Bystryn J.C., Chernyavsky A.I., Frusić-Zlotkin M., Gniadecki R., Lotti R., et al. Apoptolysis: a novel mechanism of skin blistering in pemphigus vulgaris linking the apoptotic pathways to basal cell shrinkage and suprabasal acantholysis. Exp Dermatol 2009, 18:764-770.
6. Cirillo N., Dell' Ermo A., Gombos F., Lanza A. The specific proteolysis hypothesis of pemphigus: does the song remain the same. Med Hypotheses 2008, 70:333-337.
7. Li N., Zhao M., Wang J., Liu J., Diaz L.A. Involvement of the apoptotic mechanism in pemphigus foliaceus autoimmune injury of the skin. J Immunol 2009, 182:711-717.
8. Muller E.J., Williamson L., Kolly C., Suter M.M. Outside-in signaling through integrins and cadherins: a central mechanism to control epidermal growth and differentiation?. J Invest Dermatol 2008, 128:501-516.
9. Hertl M., Eming R., Veldman C. T cell control in autoimmune bullous skin disorders. J Clin Invest 2006, 116:1159-1166.
10. Anhalt G.J., Kim S.C., Stanley J.R., Korman N.J., Jabs D.A., Kory M., et al. Paraneoplastic pemphigus. An autoimmune mucocutaneous disease associated with neoplasia. N Engl J Med 1990, 323:1729-1735.
11. Schepens I., Jaunin F., Begre N., Läderach U., Marcus K., Hashimoto T., et al. The protease inhibitor alpha-2-macroglobulin-like-1 is the p170 antigen recognized by paraneoplastic pemphigus autoantibodies in human. PLoS One 2010, 5:e12250.
12. Martin K., Werth V., Villanueva E., Segall J., Murrell D.F. Interventions for pemphigus vulgaris and pemphigus foliaceus. Cochrane Database Syst Rev 2009, 1:CD006263.
13. Kasperkiewicz M., Schmidt E. Current treatment of autoimmune blistering diseases. Curr Drug Discov Technol 2009, 6:270-280.
14. Hertl M., Zillikens D., Borradori L., Bruckner-Tuderman L., Burckhard H., Eming R., et al. Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases. J Dtsch Dermatol Ges 2008, 6:366-373.
15. Schmidt E., Goebeler M., Zillikens D. Rituximab in severe pemphigus. Ann N Y Acad Sci 2009, 1173:683-691.
16. Schmidt E., Brocker E.B., Goebeler M. Rituximab in treatment-resistant autoimmue blistering skin disorders. Clin Rev Allergy Immunol 2008, 34:56-64.
17. Peterson J.D., Chan L.S. Effectiveness and side effects of anti-CD20 therapy for autoantibody-mediated blistering skin diseases: a comprehensive survey of 71 consecutive patients from the Initial use to 2007. Ther Clin Risk Manag 2009, 5:1-7.
18. Amagai M., Ikeda S., Shimizu H., Iizuka H., Hanada K., Aiba S., et al. A randomized double-blind trial of intravenous immunoglobulin for pemphigus. J Am Acad Dermatol 2009, 60(4):595-603.
19. Zillikens D., Derfler K., Eming R., Fierlbeck G., Goebeler M., Hertl M., et al. Recommendations for the use of immunoapheresis in the treatment of autoimmune bullous diseases. J Dtsch Dermatol Ges 2007, 5:881-887.
20. Di Bisceglie M.B., Lucchese A., Crincoli V. Pemphigus: the promises of peptide immunotherapy. Immunopharmacol Immunotoxicol 2009, 31:509-515.
21. Marazza G., Pham H.C., Schärer L., Pedrazzetti P.P., Hunziker T., Trüeb R.M., et al. Incidence of bullous pemphigoid and pemphigus in Switzerland: a 2-year prospective study. Br J Dermatol 2009, [Epub ahead of print].
22. Bertram F., Bröcker E.B., Zillikens D., Schmidt E. Prospective analysis of the incidence of autoimmune bullous disorders in Lower Franconia, Germany. J Dtsch Dermatol Ges 2009, 7:434-440.
23. Kasperkiewicz M., Zillikens D. The pathophysiology of bullous pemphigoid. Clin Rev Allergy Immunol 2007, 33:67-77.
24. Mutasim D.F. Autoimmune bullous dermatoses in the elderly: an update on pathophysiology, diagnosis and management. Drugs Aging 2010, 27:1-19.
25. Schmidt E., Zillikens D. Research in practice: diagnosis of subepidermal autoimmune bullous disorders. J Dtsch Dermatol Ges 2009, 7:296-300.
26. Wilczek A., Sticherling M. Concomitant psoriasis and bullous pemphigoid: coincidence or pathogenic relationship?. Int J Dermatol 2006, 45:1353-1357.
27. Mihai S., Chiriac M.T., Herrero-Gonzalez J.E., Goodall M., Jefferis R., Savage C.O., et al. IgG4 autoantibodies induce dermal-epidermal separation. J Cell Mol Med 2007, 11(5):1117-1128.
28. Iwata Y., Komura K., Kodera M., Usuda T., Yokoyama Y., Hara T., et al. Correlation of IgE autoantibody to BP180 with a severe form of bullous pemphigoid. Arch Dermatol 2008, 144(1):41-48.
29. Dresow S.K., Sitaru C., Recke A., Oostingh G.J., Zillikens D., Gibbs B.F. IgE autoantibodies against the intracellular domain of BP180. Br J Dermatol 2009, 160(2):429-432.
30. Chan L.S., Ahmed A.R., Anhalt G.J., Bernauer W., Cooper K.D., Elder M.J., et al. The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators. Arch Dermatol 2002, 138:370-379.
31. Joly P., Roujeau J.C., Benichou J., Picard C., Dreno B., Delaporte E., et al. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med 2002, 346:321-327.
32. Wang G., Ujiie H., Shibaki A., Nishie W., Tateishi Y., Kikuchi K., et al. Blockade of autoantibody-initiated tissue damage by using recombinant fab antibody fragments against pathogenic autoantigen. Am J Pathol 2010, 176:914-925.
33. Sitaru A.G., Sesarman A., Mihai S., Chiriac M.T., Zillikens D., Hultman P., et al. T cells are required for the production of blister-inducing autoantibodies in experimental epidermolysis bullosa acquisita. J Immunol 2010, 184:1596-1603.
34. Alonso-Llamazares J., Gibson L.E., Rogers R.S. Clinical, pathologic, and immunopathologic features of dermatitis herpetiformis: review of the Mayo Clinic experience. Int J Dermatol 2007, 46:910-919.
35. Briani C., Samaroo D., Alaedini A. Celiac disease: from gluten to autoimmunity. Autoimmun Rev 2008, 7:644-650.
36. Koskinen L.L., Korponay-Szabo R., Viiri K., Juuti-Uusitalo K., Kaukinen K., Lindfors K., et al. Myosin IXB gene region and gluten intolerance: linkage to coeliac disease and a putative dermatitis herpetiformis association. J Med Genet 2008, 45:222-227.
37. Hull C.M., Liddle M., Hansen N., Meyer L.J., Schmidt L., Taylor T., et al. Elevation of IgA anti-epidermal transglutaminase antibodies in dermatitis herpetiformis. Br J Dermatol 2008, 159(1):120-124.
38. Caproni M., Antiga E., Melani L., Fabbri P. Guidelines for the diagnosis and treatment of dermatitis herpetiformis. J Eur Acad Dermatol Venereol 2009, 23:633-638. Italian Group for Cutaneous Immunopathology.
39. Lewis N.R., Logan R.F., Hubbard R.B., West J. No increase in risk of fracture, malignancy or mortality in dermatitis herpetiformis: a cohort study. Aliment Pharmacol Ther 2008, 27(11):1140-1147.